Read about our COVID-19 Response. LEGAL Terms of Use Thank you for visiting the Cerus Corporation Web site. The materials on this Web site are provided as a service to our investors, to the media, and to research and medical professionals seeking general information about our technology and our products. The information contained in this Web site is not intended to provide investment and/or medical advice. While Cerus intends to periodically update the information contained in this Web site, it makes no representations or warranties as to its accuracy or completeness. Access to and use of the Cerus Web site is subject to the terms and conditions set forth in this Legal Information page and any other applicable laws, statutes and/or regulations. Cerus may revise these terms and conditions by updating this page in the future. Ownership of Materials The information and graphical materials on this Web site are copyrighted and are protected. You may bookmark these pages, distribute URL address infomation, and print or copy pages published on our Web site for your own non-commercial reference use only, provided that any copies you make retain all copyright notices and legal information contained herein. Any other use of the materials on this Web site without Cerus’ prior written permission is prohibited. Links to Third Party Web Pages and Web Sites Any links to third party Web pages from this Web site are provided for your convenience only. Cerus does not monitor, author, edit, or endorse any information provided in these third party pages and assumes no responsibility for the accuracy of their content. Communications with Cerus We at Cerus appreciate your thoughts, ideas and communications. However, please note: DO NOT send Cerus any information that you consider to be confidential. Unless Cerus has previously entered into a written Nondisclosure Agreement signed by both you and Cerus, Cerus, its successors, assigns, licensees and collaborators, may make full use of any communications that you have with Cerus, including any information, suggestion or idea you may communicate, without obligation to you. Such communication will not be maintained by Cerus as confidential, and Cerus may reproduce, publish, broadcast or post such communication at its sole discretion. Safe Harbor Statement Statements in this Web site, including, among others, statements regarding potential efficacy of products, clinical trials, regulatory filings and approvals, product development and commercial potential and potential revenue are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from any forward-looking statements as a result of certain factors, including the risks and uncertainties inherent in developing biotechnology products based on new technologies, the timing and results of any clinical trials and other development activities, market acceptance of any products, actions by regulatory authorities at any stage of the development process, the availability of governmental or third party reimbursement for the use of any products, the size of the markets for any products, competitive conditions, manufacturing capabilities, development and testing of additional configurations of any products, product liability, Cerus’ limited operating history, additional financing activities, protection of intellectual property rights, volatility in Cerus’ stock price, legal proceedings, on-going compliance with the requirements of the Sarbanes-Oxley Act of 2002 and other factors discussed in Cerus’ most recent filings with the Securities and Exchange Commission. Cerus assumes no obligation to update any forward-looking statements. Trademarks INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc. Regulatory Approval The INTERCEPT Blood System for both platelets and plasma has received CE Mark approval in Europe and FDA approval in the United States. Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2020 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. MKT-EN 00473 v.1.0 About Cerus About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK